Glaukos Corporation

GKOS ·Healthcare, Medical Devices, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-187.7M $-146.4M $-134.7M $-99.2M $-49.6M $-120.3M $15.4M $-13.0M
Depreciation & Amortization $38.1M $35.7M $33.7M $31.6M $29.7M $29.4M $6.3M $6.3M
Depreciation $11.0M $10.9M $8.7M $6.7M $4.7M $4.5M — —
Amortization $27.1M $24.7M $24.9M $24.9M $24.9M $24.9M — —
Stock-Based Compensation $63.2M $50.2M $43.5M $38.6M $30.1M $46.5M $36.4M $25.7M
Net Cash from Operating Activities $-14.8M $-61.3M $-57.8M $-33.1M $24.7M $-23.0M $-369.0K $18.9M
Investing Activities
Capital Expenditures $7.7M $6.3M $20.2M $30.3M $47.8M $6.9M $4.7M $10.3M
Business Acquisitions $12.4M — — — — — — —
Net Cash from Investing Activities $-77.6M $47.8M $14.1M $44.8M $-58.2M $-205.1M $43.4M $-26.4M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $11.9M $91.5M $15.0M $6.3M $39.3M $262.5M $-9.6M $21.6M
Net Change in Cash $-79.7M $75.0M $-27.3M $16.5M $4.0M $34.4M $33.2M $14.1M
Free Cash Flow $-22.5M $-67.6M $-78.0M $-63.3M $-23.1M $-29.9M $-5.1M $8.5M
← Newer Page 1 of 2 Older →